Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753340 | 0.95 | KDR (0.32) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL31542606 | 0.89 | ALOX5AP (0.32) | RIPK2GCKALOX5APFEN1PLA2G7 | |
| SCHEMBL15901459 | 0.85 | LOXL2 (0.42) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL29769062 | 0.85 | LOXL2 (0.42) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL21098839 | 0.83 | GCK (0.38) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL30753338 | 0.81 | FEN1 (0.34) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL30753344 | 0.78 | FEN1 (0.34) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL30753333 | 0.77 | LOXL2 (0.38) | KDRRIPK2GCKALOX5APFEN1 | |
| SCHEMBL15901323 | 0.76 | GCK (0.39) | RIPK2GCK | |
| SCHEMBL24998894 | 0.75 | LOXL2 (0.40) | KDRRIPK2GCKALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565587-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B Technologies (Beijing) Co., Limited (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2025-05-15 | — | — | US | disclosed |
| WO-2024027116-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | 4B TECHNOLOGIES (BEIJING) CO., LIMITED (CN) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154153-A1 | DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF | PLA2G4A, PLA2G1B, PLA2G4B | KDR 3045/4885RIPK2 2563/4885GCK 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.